Themis nabs €10M series C for chikungunya, Zika push

Mosquito
An investment fund formed by J.P. Morgan and the Gates Foundation led Themis' €10 million series C.

About a year after a €10 million series B, Austrian vaccine company Themis has secured a series C in the same amount led by new investor Global Health Investment Fund (GHIF).

The money will again be used to advance a chikungunya vaccine, which is being tested in three phase 2 trials in central Europe, Puerto Rico and U.S. mainland, a Zika candidate that entered human testing last April, as well as other preclinical assets against RSV and norovirus. These vaccines are based on Themis’ proprietary Themaxyn platform developed at Institut Pasteur, which uses a measles vaccine as a vector to carry antigen-encoding genes.

Themis recently reported positive interim results from the European trial on its chikungunya vaccine, the most advanced program in its pipeline. The vaccine induced neutralizing antibodies in all treatment groups 56 days after first immunization, and the seroconversion rate reached 95% after two doses.

Webinar

Bioavailability Enhancement – Industry Insights, Key Challenges & Advanced Development Solutions

Join this webcast on Tuesday, June 16 as experts present the exclusive survey findings and introduce innovative scalable drug delivery technologies proven to address the industry’s growing need for improving solubility and enhancing bioavailability.

The European trial will have final readouts midyear, but CEO Erich Tauber, Ph.D., told FierceVaccines that the U.S. and Puerto Rico trials were delayed by hurricanes Harvey and Maria. The program also received £3 million worth of funding from the U.K.’s National Institute for Biological Standards and Control to develop a monkey challenge model and to conduct a small phase 1 in the country.

RELATED: Chikungunya vaccines: Themis, Bharat Biotech kick off new testing

New investor GHIF led the round because it sees “tremendous potential in Themis’ technology platform” and is “impressed with Themis’ ability to navigate complex clinical, regulatory and manufacturing issues,” commented GHIF partner Glenn Rockman, who has joined Themis’ board.

While at J.P. Morgan’s investment banking division, Rockman worked with the Bill & Melinda Gates Foundation to build GHIF. The fund is focused on late-stage projects in drugs, vaccines and diagnostics for diseases that burden low-income populations. It has supported projects in malaria, tuberculosis, HIV/AIDS, cholera and preventable causes of maternal and infant mortality.

No vaccine is available for either chikungunya or Zika, both mosquito-borne viruses. In chikungunya, Themis is notably vying against PaxVax, which in-licensed its candidate from the NIH, and India’s Bharat Biotech and secretive Moderna are working on their phase 1 programs. More candidates are competing in Zika, including one from Inovio, a U.S. Army-developed shot Sanofi recently walked away from, and one from a Valneva-Emergent BioSolutions partnership, among others.

Suggested Articles

Not wanting to be left behind in the COVID-19 vaccine race, Europe is stepping up its efforts secure supplies if any immunizations prove effective.

The Trump administration has selected five COVID-19 vaccines for Operation Warp Speed, the NYT reports, with Big Pharma dominating the list.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot.